Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  SIX SWISS EXCHANGE AG  >  Roche Holding Ltd.       CH0012032048

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ( CHF)
Sales 2016 51 177 M
EBIT 2016 17 949 M
Net income 2016 11 602 M
Debt 2016 10 850 M
Yield 2016 3,41%
Sales 2017 53 759 M
EBIT 2017 19 300 M
Net income 2017 12 840 M
Debt 2017 5 644 M
Yield 2017 3,63%
P/E ratio 2016 18,35
P/E ratio 2017 16,69
EV / Sales2016 4,43x
EV / Sales2017 4,12x
Capitalization 216 109 M
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the diagnostics and pharmaceuticals segments.The pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The diagnostic segment... 
Sector
Pharmaceuticals
Calendar
08/03Presentation
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
07/22 ROCHE : F. Hoffmann-La Roche Announces Half Year Results 2016
07/22 ROCHE : Diagnostics Operations Assigned Patent
07/22 ROCHE : Site finds its buyer
07/22 UNILEVER : and Roche results better than expected
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/21 ROCHE : Bloomfield firm buys roche campus; medical school lease signed
07/21 ROCHE : S campus sold; lease signed for medical school
07/21DJROCHE : Sales Rise on Cancer Drugs -- Update
07/21DJROCHE : Sales Rise on Cancer Drugs
07/21DJROCHE : Net Profit Up 4% in First Half
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 298  CHF
Spread / Average Target 19%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Daniel O'Day COO-Roche Pharmaceuticals Division
Roland Diggelmann COO-Roche Diagnostics Division
Alan Hippe Chief Financial & Information Technology Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.218 832
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.53%219 526
ROCHE HOLDING LTD.-9.55%218 832
MERCK & CO., INC.11.36%162 815
More Results